Business
OBD presents latest EpiSwitch data at ASH Summit
OBD presents latest EpiSwitch data at ASH Summit.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 8050U Oxford BioDynamics PLC 17 July 2018 \n\n17 July 2018\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes\n \n· EpiSwitch™ biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 \n· EpiSwitch™ biomarkers have been shown to offer prognostic stratifications in lymphoma patients\n· Data presented at the ASH Summit on Emerging Immunotherapies for Hematologic Diseases on 13 July 2018, in Washington DC\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has presented its latest EpiSwitch™ data in a plenary talk at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematologic Diseases, 12-13 July 2018, Washington DC, entitled: \"Chromosome Conformation Monitoring for Prognostic Stratifications of Non-responders to Cancer Immunotherapies: Deconvolution of Epigenetic data with EpiSwitch™.\"\n \nDr Alexandre Akoulitchev, Chief Scientific Officer of Oxford BioDynamics, presented data on prognostic blood-based stratifications of patients with a common type of Non-Hodgkin lymphoma, and on predictive biomarkers for response to treatment with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1. Data presented from several indications successfully demonstrated that EpiSwitch™ epigenetic biomarkers identified in patients' blood could help identify patients that will not respond adequately to anti-PD-1 or anti-PD-L1 monotherapy. Based on further analysis of more than 126 patients, this validation study demonstrated 94% accuracy in predicting response to the anti-PD-L1 treatment.\n \nImmunotherapy, particularly immune checkpoint inhibitor PD-1/PD-L1 treatments, is a type of therapy that harnesses a person's immune system to fight cancer cells. Lymphomas represent a broad range of blood cancers based on diseases of white cells. Whi...